Halo: The Master Chief Collection to get fixes, upgrades for Xbox One X

Halo: The Master Chief Collection will be updated with “enhancements” for the Xbox One X, developer 343 Industries announced during a livestream yesterday.

The studio offered few details on the upgrades, although it said that The Master Chief Collection’s Xbox One X update will offer more than improved graphics.

In a blog post, 343 said that in addition to enhancements for the 4K-capable console, the patch will feature “fixes, improvements and upgrades to the core game to help bring it forward and modernize many of the game’s systems to take advantage of Xbox platform advancements since its original launch.” For instance, 343 head Bonnie Ross said during the livestream that the latest version of the Xbox platform “has amazing improvements to matchmaking, which we’ll benefit from.”

Microsoft released The Master Chief Collection in November 2014. It is a compilation for the Xbox One of the first four Halo games — Halo: Combat Evolved, Halo 2, Halo 3 and Halo 4 — all of which originally came out on the Xbox or Xbox 360. The package is a complex bundle of very different titles, and 343 noted, “While we’re incredibly excited by this opportunity to go back under the hood with MCC, it’s not going to be easy nor is it going to happen overnight.”

The Master Chief Collection received praise for its four Halo campaigns, but for weeks after launch, severe network issues rendered the games’ multiplayer components nearly unplayable. Ross eventually issued a formal apology, and 343 later offered a free make-good to affected players: a remaster of Halo 3: ODST’s campaign. The history makes it encouraging, and not surprising, that 343 is being cautious with the Xbox One X update for The Master Chief Collection.

“To help facilitate this process we’re planning to roll out a public ‘flighting’ program for MCC to allow for iterative patches and updates while testing in the wild at large scale,” said 343. The studio plans to begin testing the compilation with players in spring 2018.

As for the most recent Halo game, 2015’s Halo 5: Guardians, 343 is working with Skybox Labs on the game’s Overtime update. Scheduled for November, the Overtime update “takes advantage of the extra power of Xbox One X to deliver higher visual fidelity for players” — namely, native 4K resolution and high dynamic range (HDR) color. There’s no word yet on whether the Overtime update will be released in time for the Xbox One X’s launch on Nov. 7.

Safety is Elon Musk’s chief concern for new SpaceX rocket

In response to a question asking what will be sent in the first missions to Mars, Musk responded that SpaceX’s goal will be to transport colonists and make sure the basic necessities for survival were in place. He compared it to building the transcontinental railway. “A vast amount of industry will need to be built on Mars by many other companies and millions of people,” Musk explained, which makes clear he’s not planning on SpaceX colonizing Mars singlehandedly.

Musk addressed safety issues when it comes to using BFR for transportation around the Earth. SpaceX’s goal is to reach (or even exceed) current levels of safety for passenger airlines. The focus of the Raptor engines is on reliability; they’ll have a flak shield to protect them, as well as more engines than most airlines to ensure redundancy. “That will be especially important for point to point journeys on Earth,” Musk said. “The advantage of getting somewhere in 30 mins by rocket instead of 15 hours by plane will be negatively affected if ‘but also, you might die’ is on the ticket.

Safety was also cited as the reason that the Raptor engines were downscaled from roughly 300 tons-force to 170 tons-force. After cheekily responding to a question addressing the downscaling with, “We chickened out,” Musk cited the possibility of engine failure as the reason behind the decision. The ship’s mass decreased between the previous IAC talk and this one; the engine downscaling is in proportion to that. “In order to be able to land the BF Ship with an engine failure at the worst possible moment, you have to have multiple engines,” he explained “The difficulty of deep throttling an engine increases in a non-linear way, so 2:1 is fairly easy, but a deep 5:1 is very hard.”

Musk also addressed his vision for a future city on Mars. The illustration provided shows ships that appear to have been used to construct the colony. One commenter asked whether that meant the first two spaceships would remain on Mars permanently as a part of the city. Musk’s answer was succinct: “Wouldn’t read too much into that illustration.”

Another commenter asked about landing sites for the Mars base. Were the priorities on science or safety? As was a theme throughout this AMA, safety and survival are the paramount concerns. “Landing site needs to be low altitude to maximize aero braking, be close to ice for propellant production and not have giant boulders,” he said. “Closer to the equator is better too for solar power production and not freezing your ass off.”

If you’re interested in technical specs and getting down into the nitty gritty, you should check out the full AMA for yourself. Musk answers quite a few detailed and well thought out questions (including a warning that the future design of the fuel tanker for the BFS will look “kinda weird.”)

Xbox chief says Sony won’t allow cross-platform Minecraft, probably never will

The release last month of the Better Together update for Minecraft brought together Minecraft players on most of the game’s many platforms: the Xbox One, Windows 10, mobile, and VR versions of the game now all use the same engine and can all play together without borders. Servers and content will be accessible from any Better Together platform. Microsoft has also announced that this version of the game will be coming to the Nintendo Switch, and it, too, will be able to join in the cross-platform play.

But one major platform is being left behind: PlayStation 4. Minecraft players on the PlayStation 4 will only be able to play with other PlayStation 4 users. Not because of any technical constraint, but because Sony won’t allow it.

Speaking to Gamespot, Xbox chief Phil Spencer said Sony regards platform lock-in as a way of driving sales and “that reason [for blocking cross-platform play] is not going away.” Spencer doesn’t hold out much hope for things changing, either: “I’m never going to call anything a lost cause, but I think some of the fundamental reasons and certain scenarios—they’re not really going away.”

In June, Sony execs insisted that the company has no “profound philosophical stance” against cross-platform play, and it has permitted play between the PC and PlayStation 4. But cross-console play is clearly a sticking point. While Microsoft isn’t the first developer to cite Sony’s refusal to allow cross-platform play—Rocket League developer Psyonix and Gwent developer CD Projekt have both blamed Sony for the limitation—this is the first time the company has itself fallen foul of Sony’s restrictions. Moreover, Spencer’s comments make clear that Sony’s desire to create lock-in appears to be its overwhelming concern.

If one game could make Sony reconsider, the sheer size and popularity of Minecraft means that it’s surely the one. Better Together is a substantial update, and one can well imagine that it won’t be long before Minecraft players start to expect—and even demand—the ability to play on the same servers regardless of whether they’re using their consoles, their phones, or even their PCs. For now, however, Sony appears content to deny the users of its platform access to the larger Minecraft universe.

SpaceX chief Musk unveils Interplanetary Transport System plan to colonise Mars

A billionaire tech entrepreneur plans to land at least two cargo ships on Mars by 2022 – using a rocket he claims will also be able to take humans anywhere on Earth within an hour.

Elon Musk unveiled his updated plans for colonising the Red Planet at the International Astronautical Congress in Adelaide, Australia.

“I feel fairly confident we can build the ship and be ready for the launch in five years. Five years seems like a long time for me,” said the SpaceX chief executive, who also revealed plans for a lunar base.

Mr Musk wants craft carrying crews to Mars to arrive in 2024, with the cargo ships having placed power, mining and life-support infrastructure on the planet two years earlier.

SpaceX currently has a fleet of three spacecraft, which the Tesla boss wants to become obsolete.

Instead, Mr Musk told the audience his company will begin stockpiling the Falcon 9, Falcon Heavy and Dragon spacecrafts, and put all of its resources into building the Interplanetary Transport System (ITS) – codenamed the BFR, or “Big F****** Rocket”.

Mr Musk believes SpaceX can finance its Mars ambitions from its current work launching satellites and servicing the International Space Station (ISS).

The 46-year-old unveiled the combo rocket and spaceship at the same conference last year, but announced a stripping back of the BFR to contain fewer main engines – 31 – while he also released a concept video showing the spacecraft’s potential journey between New York and Shanghai.

“BFR will take you anywhere on Earth in less than 60 mins,” Mr Musk wrote on Twitter. The video added that “most long-distance trips” would take less than 30 minutes.

SpaceX plans to start building the first spaceship, which Mr Musk said is the company’s cheapest yet, by the middle of 2018.

The ITS would be capable of carrying around 100 people spread out over 40 cabins, including common areas and an entertainment system.

Mr Musk also shared concept images of the spacecraft landed on Mars, next to a human settlement, saying he wanted to make the Red Planet “a nice place to be” with a sustainable human population of around one million.

“I can’t think of anything more exciting than being out there among the stars,” he said.

It adds to the list of Mr Musk’s other outlandish-sounding ventures, which includes Hyperloop, a system intended to carry humans through tubes in pressurised cabins at speeds of around 600mph, and Neuralink – a startup exploring how to connect the human brain to computers.

Uber whistleblower and company HR chief clash online

It’s been eight months since former Uber engineer Susan Fowler upended the ride-hailing company with her explosive blog post accusing company managers of sexual harassment and sexism. But Uber’s new human resources chief, who is largely in charge of fixing the cultural issues Fowler highlighted, reportedly hasn’t met with Fowler — and doesn’t plan to.

That’s according to a Q&A The Wall Street Journal published with HR head, Liane Hornsey, on Monday.

Hornsey joined Uber in December, a month after Fowler left, and a month before Fowler published the blog post. When asked if she’d reached out to Fowler, Hornsey said no.

Xbox One Marketing Chief Impressed And Surprised By Sony’s PlayStation 4 Pro

We often see in sports mutual respect by the world’s top athletes, even ones that are bitter rivals. Case in point, Larry Bird and Magic Johnson fought tooth and nail on the basketball court for many years, but each respected the other’s game, and they eventually became friends. In a similar vein, Albert Penello, Microsoft’s head of marketing, said Sony deserves “a lot of credit” for what the company did in putting together the PlayStation 4 Pro.

Microsoft is getting ready to release the world’s most powerful game console, the Xbox One X. The company’s aim is to enable 4K resolution gameplay at 60 frames per second. Sony’s PS4 Pro is a direct competitor to the Xbox One X, which came out nearly a year ago, in November 2016.

PlayStation 4 Pro

“I give them a lot of credit for what they did there,” Penello told MCV. “But for me, the most interesting observation is that we both arrived at a similar idea even if the execution is slightly different. This business tends to diverge and converge in interesting ways, and obviously we don’t know what they’re doing. We don’t have insight into what their plans are, so when they announced the Pro, I was a surprised as anybody else was.”

Like the Xbox One X, the PS4 Pro is an upgraded version of its predecessor and is intended for 4K resolution gameplay. However, as Penello notes the two consoles approach things differently. While Sony has said the PS4 Pro is technically capable of native 4K gaming, the console renders most games at a lower resolution and then upconverts to 4K. Sony calls this “dynamic 4K.”

“They had a different idea in mind for what they wanted to build, so in retrospect it may seem like we were reacting to what they were doing. But people in the business know that this has been in the works for years, and we have to lock the specs years in advance,” Penello added.

Microsoft’s big marketing pitch is that the Xbox One X delivers “true 4K” gaming, in that it has the hardware necessary to render a native 3840×2160 resolution experience, rather than rendering at a lower resolution and outputting at 4K. That is a point that Microsoft will make again and again when promoting the Xbox One X, though at the same time, there appears to be some level of mutual respect between Microsoft and Sony.

‘).insertAfter(jQuery(‘#initdisqus’));
}
loadDisqus(jQuery(‘#initdisqus’), disqus_identifier, url);

}
else {
setTimeout(function () { disqusDefer(); }, 50);
}
}

disqusDefer();

function loadDisqus(source, identifier, url) {

if (jQuery(“#disqus_thread”).length) {
jQuery(“#disqus_thread”).remove();
}
jQuery(‘

‘).insertAfter(source);

if (window.DISQUS) {

DISQUS.reset({
reload: true,
config: function () {
this.page.identifier = identifier;
this.page.url = url;
}
});

} else {

//insert a wrapper in HTML after the relevant “show comments” link

disqus_identifier = identifier; //set the identifier argument
disqus_url = url; //set the permalink argument

//append the Disqus embed script to HTML
var dsq = document.createElement(‘script’); dsq.type = ‘text/javascript’; dsq.async = true;
dsq.src = ‘https://’ + disqus_shortname + ‘.disqus.com/embed.js’;
jQuery(‘head’).append(dsq);

}

jQuery(‘.show-disqus’).show();
source.hide();
};

function disqusEvent()
{
idleTime = 0;
}

Apple’s chief lawyer retires as it battles Qualcomm and Samsung

Apple’s top lawyer, who has guided it through battles with Samsung and Qualcomm and taken on the US government over iPhone security, is retiring, as the Silicon Valley company brings in a new general counsel from Honeywell.

Bruce Sewell, who is 59, became Apple’s general counsel in 2009 and will step down at the end of the year.

Kate Adams, formerly of US industrial conglomerate Honeywell, will take a seat on Apple’s executive team, reporting directly to chief executive Tim Cook, and lead global security, as part of her new role as general counsel. 

Mr Sewell’s departure comes as Apple is taking on Qualcomm on several fronts, accusing the chipmaker of overcharging for its wireless modem technology and patents, in a legal battle that has also embroiled several of the iPhone’s top suppliers in Asia. 

Its patent battle against Samsung over iPhone designs is still rolling through the courts.

Apple is also fighting the European Commission over what Brussels claims is €13bn in illegal tax benefits from Ireland. This week, the EU said it would take Ireland to court to force it to recover the sum from Apple. 

“The move takes on greater significance given the number of battles Apple is facing in and out of the courtroom,” said Neil Cybart, an Apple analyst at Above Avalon.

“While there is never a perfect time for such a transition, it makes sense for Apple to pass on the baton to a new general counsel sooner rather than later given the company’s intensifying war with Qualcomm.”

Mr Cook said in a statement on Friday that he was thrilled to welcome Ms Adams, who will help steer the company’s legal strategy on issues ranging from customer privacy to intellectual property. 

“She’s a seasoned leader with outstanding judgment and has worked on a wide variety of legal cases globally. Throughout her career she’s also been an advocate on many of the values we at Apple hold dear,” he said.

He also thanked Mr Sewell for having “tirelessly defended our IP, our customers’ right to privacy and our values”.

Apple has used privacy and security issues to differentiate itself from Silicon Valley rivals such as Google and Amazon.

In 2016, it found itself in conflict with the US government, when FBI investigators into the San Bernardino shooting asked for assistance in circumventing the encryption that locked the attacker’s iPhone.

Apple, whose legal response was led by Mr Sewell, argued that it could not help the FBI break into the device because doing so would compromise all its customers’ security. 

Ms Adams said that she was “excited to help Apple continue to grow and evolve around the world, protecting their ideas and IP, and defending our shared values”.

To replace Ms Adams, Honeywell on Friday named Anne Madden, who has served as vice-president of corporate development and global head of mergers & acquisitions since 2002, as its new general counsel.

Before joining Apple, Mr Sewell worked in Intel’s legal team for many years. He also serves as a director of Vail Resorts, which owns ski resorts including Whistler in Canada, Northstar in California’s Lake Tahoe and Park City, Utah. 

In line with other Apple executives’ pay, Mr Sewell received $22.8m in total compensation in 2016, according to regulatory filings, including $20m worth of stock awards and $1m salary.

Acer Therapeutics Appoints Dr. William T. Andrews as Chief Medical Officer Nasdaq:ACER

CAMBRIDGE, Mass., Oct. 05, 2017 (World NEWSWIRE) — Acer Therapeutics Inc., (Nasdaq:ACER), a pharmaceutical enterprise centered on the acquisition, enhancement and commercialization of therapies for significant rare and ultra-rare disorders with essential unmet medical will need, right now announced the appointment of William T. Andrews, M.D., FACP as Main Medical Officer of the Firm to be successful Robert D. Steiner, M.D. in that place.

“We are happy to welcome Dr. Andrews to the executive management group, as we keep on to properly and swiftly advance our lead products prospect, EDSIVO™, a possible existence-conserving remedy for individuals with vEDS,” said Chris Schelling, CEO and Founder of Acer. “Dr. Andrews brings remarkable knowledge to this job and will be instrumental in preparing our NDA submission of EDSIVO™, which we assume to complete in the 1st 50 % of 2018, and we glimpse ahead to his advice in the medical marketplace as we approach for our next actions. We thank Dr. Steiner for his considerable contributions to Acer through a essential time in the Company’s expansion.”

About William T. Andrews, M.D., FACP
Dr. Andrews joins Acer Therapeutics as Main Medical Officer immediately after obtaining worked in the biotech/pharmaceutical industry for 17 many years in each Medical Advancement and Medical Affairs in multiple therapeutic spots, with a concentrate and in depth knowledge in rare disorders.  Dr. Andrews has considerable medical marketplace and products start knowledge, obtaining served as the medical lead for 6 products launches, like Xopenex HFA®, Brovana®, Alvesco®, Omnaris®, Catena®, and Juxtapid®.  Most not long ago, he presented strategic consulting expert services to rare illness companies in Medical Advancement, Medical Affairs, Go-To-Market/Start setting up, and Business Advancement/Company Technique. Earlier, Dr. Andrews held senior management positions and positions of increasing obligation at Aegerion Prescribed drugs, Santhera Prescribed drugs, Sepracor, and ClinQuest.  He acquired his undergraduate degree in Biology from Harvard University and his M.D. degree from Yale University Faculty of Medicine. Dr. Andrews practiced medicine for 7 many years comprehensive-time and 11 many years component-time in the Boston location as a board-certified Internist and an Attending Doctor at Brigham and Women’s Healthcare facility, and was on the Medical College at Harvard Medical Faculty.

About Acer Therapeutics
Acer, headquartered in Cambridge, MA, is a pharmaceutical enterprise centered on the acquisition, enhancement and commercialization of therapies for individuals with significant rare and ultra-rare disorders with essential unmet medical will need. Acer’s late-phase clinical pipeline incorporates two candidates for serious genetic diseases for which there are few or no Fda-accepted treatment plans: EDSIVO™ (celiprolol) for vEDS, and ACER-001 (a totally style-masked, quick release formulation of sodium phenylbutyrate) for urea cycle diseases (UCD) and Maple Syrup Urine Illness (MSUD). There are no Fda-accepted medication for vEDS and MSUD and minimal selections for UCD, which collectively influence much more than 4,000 individuals in the United States. Acer’s merchandise have clinical proof-of-concept and mechanistic differentiation, and Acer intends to seek out acceptance for them in the U.S. by applying the regulatory pathway founded beneath section 505(b)(2) of the Federal Food items, Drug, and Beauty Act, or FFDCA, that will allow an applicant to count for acceptance at minimum in component on 3rd-party data, which is envisioned to expedite the preparing, submission, and acceptance of a internet marketing application.

For much more data, go to www.acertx.com.

Ahead-Wanting Statements
This press release contains “forward-searching statements” that entail considerable challenges and uncertainties for needs of the risk-free harbor presented by the Personal Securities Litigation Reform Act of 1995. All statements, other than statements of historical details, provided in this press release regarding system, future operations, future financial place, future earnings, projected bills, prospects, strategies and targets of management are ahead-searching statements. Illustrations of these kinds of statements consist of, but are not minimal to, statements relating to the possible for EDSIVO™ (celiprolol) and ACER-001 to safely and proficiently focus on disorders the adequacy of the company’s money to aid its future operations and its ability to properly initiate and complete clinical trials and regulatory submissions the nature, system and concentrate of the enterprise and the enhancement, envisioned timeline  and commercial possible of any products candidates of the enterprise. Acer may well not truly attain the strategies, have out the intentions or meet up with the expectations or projections disclosed in the ahead-searching statements and you ought to not put undue reliance on these ahead-searching statements. This sort of statements are primarily based on management’s existing expectations and entail challenges and uncertainties. True results and effectiveness could vary materially from those projected in the ahead-searching statements as a outcome of numerous factors, like, without limitation, challenges and uncertainties associated with the ability to task future hard cash utilization and reserves essential for contingent future liabilities and small business operations, the availability of adequate resources of the enterprise to meet up with its small business targets and operational requirements, the simple fact that the results of previously scientific tests and trials may well not be predictive of future clinical trial results, the protection and industry exclusivity presented by Acer’s mental house, challenges related to the drug enhancement and the regulatory acceptance procedure and the influence of competitive merchandise and technological alterations. Acer disclaims any intent or obligation to update these ahead-searching statements to mirror gatherings or conditions that exist immediately after the day on which they have been manufactured. You ought to evaluation extra disclosures we make in our filings with the Securities and Exchange Fee, like our Quarterly Studies on Form 10-Q and our Annual Report on Form 10-K. You may well access these paperwork for no demand at http://www.sec.gov.

Investor Get in touch with:
Hans Vitzthum
LifeSci Advisors
Ph: 212-915-2568
hans@lifescieadvisors.com

Acer Therapeutics Appoints Dr. William T. Andrews as Chief Medical OfficerDr. Andrews’s Appointment Supports Acer’s Progression from Development to Potential Commercialization of Therapies

CAMBRIDGE, Mass., Oct. 05, 2017 (Globe NEWSWIRE) — Acer Therapeutics Inc., (Nasdaq:ACER), a pharmaceutical corporation centered on the acquisition, enhancement and commercialization of therapies for major uncommon and extremely-uncommon illnesses with significant unmet professional medical will need, nowadays introduced the appointment of William T. Andrews, M.D., FACP as Main Healthcare Officer of the Organization to do well Robert D. Steiner, M.D. in that posture.

“We are pleased to welcome Dr. Andrews to the government management team, as we go on to efficiently and quickly progress our guide product candidate, EDSIVO™, a potential lifestyle-preserving treatment for individuals with vEDS,” reported Chris Schelling, CEO and Founder of Acer. “Dr. Andrews brings tremendous encounter to this function and will be instrumental in making ready our NDA submission of EDSIVO™, which we anticipate to accomplish in the 1st 50 percent of 2018, and we search ahead to his guidance in the professional medical market as we program for our up coming steps. We thank Dr. Steiner for his important contributions to Acer throughout a significant time in the Company’s advancement.”

About William T. Andrews, M.D., FACP
Dr. Andrews joins Acer Therapeutics as Main Healthcare Officer after getting labored in the biotech/pharmaceutical business for 17 years in both Medical Advancement and Healthcare Affairs in a number of therapeutic locations, with a emphasis and comprehensive encounter in uncommon illnesses.  Dr. Andrews has important professional medical market and product start encounter, getting served as the professional medical guide for six product launches, such as Xopenex HFA®, Brovana®, Alvesco®, Omnaris®, Catena®, and Juxtapid®.  Most lately, he presented strategic consulting companies to uncommon disorder companies in Medical Advancement, Healthcare Affairs, Go-To-Sector/Start organizing, and Organization Advancement/Company Strategy. Earlier, Dr. Andrews held senior management positions and positions of increasing accountability at Aegerion Prescribed drugs, Santhera Prescribed drugs, Sepracor, and ClinQuest.  He been given his undergraduate degree in Biology from Harvard University and his M.D. degree from Yale University Faculty of Drugs. Dr. Andrews practiced medicine for 7 years full-time and 11 years portion-time in the Boston region as a board-certified Internist and an Attending Medical professional at Brigham and Women’s Medical center, and was on the Medical School at Harvard Healthcare Faculty.

About Acer Therapeutics
Acer, headquartered in Cambridge, MA, is a pharmaceutical corporation centered on the acquisition, enhancement and commercialization of therapies for individuals with major uncommon and extremely-uncommon illnesses with significant unmet professional medical will need. Acer’s late-phase medical pipeline involves two candidates for extreme genetic problems for which there are handful of or no Fda-accepted therapies: EDSIVO™ (celiprolol) for vEDS, and ACER-001 (a absolutely flavor-masked, rapid release formulation of sodium phenylbutyrate) for urea cycle problems (UCD) and Maple Syrup Urine Condition (MSUD). There are no Fda-accepted drugs for vEDS and MSUD and confined options for UCD, which collectively influence additional than 4,000 individuals in the United States. Acer’s merchandise have medical proof-of-strategy and mechanistic differentiation, and Acer intends to seek acceptance for them in the U.S. by applying the regulatory pathway established underneath segment 505(b)(2) of the Federal Food items, Drug, and Cosmetic Act, or FFDCA, that lets an applicant to rely for acceptance at least in portion on 3rd-bash info, which is envisioned to expedite the planning, submission, and acceptance of a internet marketing application.

For additional information and facts, go to www.acertx.com.

Forward-Wanting Statements
This push release incorporates “forward-looking statements” that require sizeable threats and uncertainties for needs of the safe harbor presented by the Non-public Securities Litigation Reform Act of 1995. All statements, other than statements of historic info, involved in this push release pertaining to approach, upcoming functions, upcoming money posture, upcoming profits, projected expenditures, prospective clients, strategies and aims of management are ahead-looking statements. Illustrations of such statements contain, but are not confined to, statements relating to the potential for EDSIVO™ (celiprolol) and ACER-001 to securely and successfully target illnesses the adequacy of the company’s money to support its upcoming functions and its means to efficiently initiate and comprehensive medical trials and regulatory submissions the nature, approach and emphasis of the corporation and the enhancement, envisioned timeline  and industrial potential of any product candidates of the corporation. Acer may possibly not actually attain the strategies, carry out the intentions or satisfy the expectations or projections disclosed in the ahead-looking statements and you need to not place undue reliance on these ahead-looking statements. This kind of statements are dependent on management’s present expectations and require threats and uncertainties. Precise outcomes and functionality could differ materially from people projected in the ahead-looking statements as a consequence of quite a few variables, such as, devoid of limitation, threats and uncertainties affiliated with the means to project upcoming income utilization and reserves necessary for contingent upcoming liabilities and business enterprise functions, the availability of enough methods of the corporation to satisfy its business enterprise aims and operational requirements, the reality that the outcomes of before scientific studies and trials may possibly not be predictive of upcoming medical trial outcomes, the defense and market exclusivity presented by Acer’s intellectual residence, threats associated to the drug enhancement and the regulatory acceptance process and the influence of competitive merchandise and technological modifications. Acer disclaims any intent or obligation to update these ahead-looking statements to reflect situations or situations that exist after the day on which they had been designed. You need to evaluation extra disclosures we make in our filings with the Securities and Exchange Commission, such as our Quarterly Studies on Type 10-Q and our Once-a-year Report on Type 10-K. You may possibly accessibility these documents for no charge at http://www.sec.gov.

Trader Contact:
Hans Vitzthum
LifeSci Advisors
Ph: 212-915-2568
hans@lifescieadvisors.com

Acer Therapeutics Appoints Dr. William T. Andrews as Chief Medical Officer

Dr. Andrews’s Appointment Supports Acer’s Progression from Development to Potential Commercialization of Therapies

CAMBRIDGE, Mass., Oct. 05, 2017 (World NEWSWIRE) — Acer Therapeutics Inc., (Nasdaq:ACER), a pharmaceutical organization focused on the acquisition, progress and commercialization of therapies for really serious exceptional and extremely-exceptional conditions with essential unmet health-related need, nowadays declared the appointment of William T. Andrews, M.D., FACP as Main Health-related Officer of the Organization to succeed Robert D. Steiner, M.D. in that place.

“We are happy to welcome Dr. Andrews to the govt management crew, as we go on to properly and quickly progress our lead merchandise applicant, EDSIVO™, a possible existence-preserving treatment for patients with vEDS,” claimed Chris Schelling, CEO and Founder of Acer. “Dr. Andrews brings huge practical experience to this purpose and will be instrumental in getting ready our NDA submission of EDSIVO™, which we anticipate to carry out in the to start with half of 2018, and we glance ahead to his assistance in the health-related marketplace as we system for our following actions. We thank Dr. Steiner for his substantial contributions to Acer for the duration of a essential time in the Company’s growth.”

About William T. Andrews, M.D., FACP
Dr. Andrews joins Acer Therapeutics as Main Health-related Officer immediately after obtaining labored in the biotech/pharmaceutical marketplace for 17 years in both equally Medical Development and Health-related Affairs in numerous therapeutic spots, with a emphasis and substantial practical experience in exceptional conditions.  Dr. Andrews has substantial health-related marketplace and merchandise start practical experience, obtaining served as the health-related lead for six merchandise launches, which includes Xopenex HFA®, Brovana®, Alvesco®, Omnaris®, Catena®, and Juxtapid®.  Most lately, he offered strategic consulting companies to exceptional sickness companies in Medical Development, Health-related Affairs, Go-To-Marketplace/Launch preparing, and Organization Development/Company System. Earlier, Dr. Andrews held senior leadership positions and positions of escalating obligation at Aegerion Prescription drugs, Santhera Prescription drugs, Sepracor, and ClinQuest.  He been given his undergraduate diploma in Biology from Harvard College and his M.D. diploma from Yale College University of Drugs. Dr. Andrews practiced drugs for 7 years full-time and 11 years portion-time in the Boston area as a board-certified Internist and an Attending Medical professional at Brigham and Women’s Healthcare facility, and was on the Medical College at Harvard Health-related University.

About Acer Therapeutics
Acer, headquartered in Cambridge, MA, is a pharmaceutical organization focused on the acquisition, progress and commercialization of therapies for patients with really serious exceptional and extremely-exceptional conditions with essential unmet health-related need. Acer’s late-stage scientific pipeline contains two candidates for severe genetic ailments for which there are couple of or no Food and drug administration-permitted remedies: EDSIVO™ (celiprolol) for vEDS, and ACER-001 (a fully style-masked, quick release formulation of sodium phenylbutyrate) for urea cycle ailments (UCD) and Maple Syrup Urine Illness (MSUD). There are no Food and drug administration-permitted medications for vEDS and MSUD and minimal choices for UCD, which collectively influence more than 4,000 patients in the United States. Acer’s products and solutions have scientific evidence-of-strategy and mechanistic differentiation, and Acer intends to seek approval for them in the U.S. by applying the regulatory pathway founded less than portion 505(b)(2) of the Federal Foods, Drug, and Cosmetic Act, or FFDCA, that permits an applicant to depend for approval at least in portion on third-social gathering information, which is expected to expedite the planning, submission, and approval of a advertising and marketing application.

For more info, pay a visit to www.acertx.com.

Forward-Seeking Statements
This press release includes “ahead-on the lookout statements” that entail significant threats and uncertainties for reasons of the secure harbor offered by the Non-public Securities Litigation Reform Act of 1995. All statements, other than statements of historical details, incorporated in this press release concerning method, upcoming functions, upcoming fiscal place, upcoming profits, projected costs, potential customers, plans and aims of management are ahead-on the lookout statements. Examples of this kind of statements include things like, but are not minimal to, statements relating to the possible for EDSIVO™ (celiprolol) and ACER-001 to safely and securely and effectively concentrate on conditions the adequacy of the firm’s money to guidance its upcoming functions and its capability to properly initiate and complete scientific trials and regulatory submissions the nature, method and emphasis of the organization and the progress, expected timeline  and industrial possible of any merchandise candidates of the organization. Acer may perhaps not essentially reach the plans, carry out the intentions or fulfill the anticipations or projections disclosed in the ahead-on the lookout statements and you should not area undue reliance on these ahead-on the lookout statements. These types of statements are centered on management’s current anticipations and entail threats and uncertainties. True outcomes and functionality could differ materially from those people projected in the ahead-on the lookout statements as a outcome of numerous factors, which includes, without having limitation, threats and uncertainties linked with the capability to project upcoming cash utilization and reserves needed for contingent upcoming liabilities and organization functions, the availability of ample methods of the organization to fulfill its organization aims and operational specifications, the actuality that the outcomes of before studies and trials may perhaps not be predictive of upcoming scientific demo outcomes, the protection and sector exclusivity offered by Acer’s mental home, threats connected to the drug progress and the regulatory approval process and the influence of competitive products and solutions and technological adjustments. Acer disclaims any intent or obligation to update these ahead-on the lookout statements to reflect events or instances that exist immediately after the date on which they had been manufactured. You should evaluation added disclosures we make in our filings with the Securities and Trade Commission, which includes our Quarterly Reviews on Form 10-Q and our Once-a-year Report on Form 10-K. You may perhaps entry these files for no demand at http://www.sec.gov.

Investor Make contact with:
Hans Vitzthum
LifeSci Advisors
Ph: 212-915-2568
hans@lifescieadvisors.com


Resource: Acer Therapeutics Inc.